TP53 and acute myeloid leukemia: In this context, venetoclax in combination with azacitidine has been a promising frontline option in older or medically unfit patients with AML, with the median OS as high as 17.5 months; however, the median OS in TP53-mutated patients with poor-risk cytogenetics treated with venetoclax and azacitidine was similar to azacitidine alone at only 5.2 months (33).